Elucidating the mode of action of the abietanes to develop potential therapeutic agents
阐明松香烷的作用模式以开发潜在的治疗药物
基本信息
- 批准号:10580286
- 负责人:
- 金额:$ 41.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:70-kDa Ribosomal Protein S6 KinasesAddressAmino AcidsAwardBiologicalBiological AssayBiological ModelsBiologyBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Epithelial CellsCancer BiologyCancer ModelCell Culture TechniquesCell DeathCell SurvivalCell modelCellsCessation of lifeChemicalsCyclizationDataDevelopmentDiseaseEndoplasmic ReticulumEnvironmentEstrogen receptor positiveEukaryotic Initiation FactorsGelGene Expression RegulationGenesGenetic TranslationGoalsKnowledgeLabelLeadLibrariesLouisianaMalignant NeoplasmsMass Spectrum AnalysisMediatingMethodologyModalityModelingMolecularNatural ProductsNeoplasm MetastasisNormal CellOntologyPathway AnalysisPathway interactionsPharmaceutical ChemistryPharmacologyPhenotypePrognosisPropertyProtein BiosynthesisProteomeProteomicsReagentRegulatory PathwayReportingResearchRhodiumSeriesSignal PathwaySignal TransductionSiteStable Isotope LabelingStructure-Activity RelationshipStudentsTestingTherapeuticTherapeutic AgentsToxic effectTraditional MedicineTranslationsUnited StatesUniversitiesanti-cancerbasebreast cancer progressioncancer cellcancer recurrencecancer subtypesclinically relevantcytotoxicdrug discoveryefficacy testinghuman diseaseimprovedinhibitorinnovationmalignant breast neoplasmmigrationmodel developmentmortalitynew therapeutic targetnovelnovel therapeuticsoverexpressionpolysome profilingprogramsscaffoldstemtargeted treatmenttooltranscriptometriple-negative invasive breast carcinoma
项目摘要
PROJECT ABSTRACT
Over expression of eukaryotic initiation factors (eIFs) has been reported in various human diseases
including breast cancer (BC). Our objective is to develop tool compounds based on the abietane natural products
to selectively target eIFs. Approximately 15-20% breast cancer cases are characterized as triple negative breast
cancer (TNBC), a subtype that lacks effective targeted therapy modalities,1 and is often plagued with
dysfunctional eIFs expression.2 Therefore, there is a need to discover new chemical matter that could selectively
targeted TNBC to reduce mortality rates associated with this disease.
We have shown that abietane natural product derivatives (SJ38) significantly reduce protein synthesis
and target eIF2/eIF4 signaling axis in TNBC cellular models. We discovered that a) SJ38 selectively inhibits
cancer cell viability at the low micromolar range (<10μM) while not affecting non-cancerous mammary epithelial
cell viability or signaling, b) SJ38 significantly reduces the expression of regulatory factors involved in protein
synthesis, and c) Stable isotope labeling with amino acids in cell culture (SILAC) proteomics provided Gene
Ontology analysis that SJ38 mainly targeted protein synthesis and Ingenuity Pathway Analysis suggested that
SJ38 exerts its anticancer effects primarily through the eIF2, and eIF4/p70S6K signaling pathway.
Our long-term goal is to elucidate SJ38 molecular mechanism in TNBC focusing on translational control. Our
study addresses a gap in knowledge to discover new therapeutic agents and biological targets to potentially treat
TNBC. We hypothesize that SJ38 reduces breast cancer progression and sensitizes cells to therapy via
translational control. We propose the following specific aims: 1) Develop a novel synthetic strategy to access a
series of diverse abietane derivatives to facilitate structure activity relationship (SAR), and target engagement
studies. 2) Determine the biological properties of the generated compounds as protein synthesis modulators and
their capability to inhibit proliferation and migration in TNBC cellular models. 3) Identify the mechanism by which
the abietanes target cancer cellular models.
IMPACT: Results from the proposed studies will provide critical knowledge towards the development of targeted
therapeutic strategies needed for the successful treatment of human diseases including cancer.
项目摘要
据报道,真核起始因子(eIF)在多种人类疾病中过度表达
包括乳腺癌(BC)。我们的目标是开发基于松香天然产物的工具化合物
选择性地针对 eIF。大约 15-20% 的乳腺癌病例属于三阴性乳腺癌
癌症(TNBC)是一种缺乏有效靶向治疗方式的亚型,1并且经常受到以下问题的困扰
eIF 表达功能失调。2 因此,需要发现新的化学物质,可以选择性地
针对 TNBC 以降低与该疾病相关的死亡率。
我们已经证明松香烷天然产物衍生物 (SJ38) 显着减少蛋白质合成
并针对 TNBC 细胞模型中的 eIF2/eIF4 信号轴。我们发现 a) SJ38 选择性抑制
低微摩尔范围 (<10μM) 下的癌细胞活力,同时不影响非癌性乳腺上皮
细胞活力或信号转导,b) SJ38 显着降低参与蛋白质的调节因子的表达
c) 细胞培养物中氨基酸的稳定同位素标记 (SILAC) 蛋白质组学提供的基因
本体分析表明SJ38主要针对蛋白质合成,Ingenuity Pathway Analysis表明:
SJ38主要通过eIF2和eIF4/p70S6K信号通路发挥抗癌作用。
我们的长期目标是阐明 SJ38 在 TNBC 中的分子机制,重点关注翻译控制。我们的
研究填补了知识空白,以发现新的治疗药物和潜在治疗的生物靶点
TNBC。我们假设 SJ38 通过以下途径减少乳腺癌进展并使细胞对治疗敏感
平移控制。我们提出以下具体目标:1)开发一种新颖的合成策略来获取
一系列不同的松香烷衍生物,以促进结构活性关系 (SAR) 和目标参与
研究。 2) 确定生成的化合物作为蛋白质合成调节剂的生物学特性和
它们在 TNBC 细胞模型中抑制增殖和迁移的能力。 3) 确定机制
松香内酯针对癌症细胞模型。
影响:拟议研究的结果将为制定有针对性的药物提供关键知识。
成功治疗包括癌症在内的人类疾病所需的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fatima R Rivas其他文献
Fatima R Rivas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fatima R Rivas', 18)}}的其他基金
Elucidating the mode of action of the abietanes to develop potential therapeutic agents_supplement
阐明松香烷类药物的作用方式以开发潜在的治疗药物_补充剂
- 批准号:
10798580 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 41.18万 - 项目类别:
Research Grant














{{item.name}}会员




